David Agus, Cedars-Sinai Medical Center‡

Naomi Aronson, BlueCross BlueShield Technology Evaluation Center*†

Suresh Arya, National Institutes of Health

Finley Austin, Roche Pharmaceuticals

Rekha Ayalur, Digene Corporation

Chris Beecher, Metabolon

Al Berg, University of Washington*†

Amy Brownawell, Life Sciences Research Office

Johanna Camara, National Institute of Standards and Technology

Jacek Capala, National Cancer Institute

David Carbone, Vanderbilt University‡

Brian Carey, Foley Hoag LLP

B. Melina Cimler, Beckman Coulter, Inc.‡

Adam Clark, National Cancer Institute

Carolyn Compton, National Cancer Institute†

Rob Danziger, PPD Biomarker Discovery Sciences

Hongue Dai, Rosetta Inpharmatics‡

Felice de Jong, Metabolon, Inc.

Nicholas de Klerk, University of Western Australia

Mark Del Vecchio, Digene Corporation

Nathan Dodder, National Institute of Standards and Technology

James Doroshow, National Cancer Institute*

Elizabeth Dupré, American Enterprise Institute

Mark Fendrick, University of Michigan‡

Helen Francis-Lang, Affymetrix

Richard Frank, GE Healthcare‡

Stephen Friend, Merck and Co., Inc.†

Felix Frueh, Food and Drug Administration

Marios Gavrielides, Food and Drug Administration

Robert Gillies, University of Arizona‡

Todd Golub, The Broad Institute of Harvard and MIT*

Mark Gorman, National Coalition for Cancer Survivorship

Steven Gutman, Food and Drug Administration

Susanne Haga, Duke University

Mark A. Heller, Wilmer Cutler Pickering Hale and Dorr*

Judith Hellerstein, University of Maryland‡

Ronald Hendrickson, Merck and Co., Inc.‡

Stuart Hogarth, University of Cambridge

Janet Jamison, National Cancer Institute

Gail Javitt, Genetics and Public Policy Center

Carolyn Jones, Advanced Medical Technology Association (AdvaMed)

Sharon Kim, Precision Therapeutics

Hon-Sum Ko, Food and Drug Administration

Walter Koch, Roche Molecular Systems‡

Paul Lambotte, Quidel Corporation

Michael Leuther, Roche Diagnostics

Rob Lipshutz, Affymetrix*

Donna Marino, HistoRx

Jay Markowitz, T. Rowe Price

Cheryl Marks, National Cancer Institute

Hela Masmoudi, George Washington University

Marilyn Mason, U.S. Department of Veterans Affairs

Lynne McBride, BD Biosciences

Robert McDonough, Aetna U.S. Healthcare†

William T. McGivney, National Comprehensive Cancer Network*†

Steve McPhail, Expression Analysis

Amita Mehratra, National Institutes of Health

Christian Meisel, F. Hoffman-La Roche AG

David Meltzer, University of Chicago*

Zhibao Mi, Precision Therapeutics

Hal Moses, Vanderbilt University†

Juli Murphy, Genetics and Public Policy Center

Ruth Neta, Department of Energy

Nancy Nelson, Journal of the National Cancer Institute

David R. Parkinson, Biogen Idec, Inc.†

Scott Patterson, Amgen, Inc.‡

Edith Perez, Mayo Clinic ‡

Omar Perez, Stanford University

Bruce Peterson, PPD Development

Michael E. Phelps, University of California, Los Angeles*

Kathryn Phillips, University of California, San Francisco ‡

William Pignato, W. J. Pignato & Associates

Indra Poola, MD, Howard University‡

M.Suzanne Pursley-Crotteau, National Cancer Institute

John Quackenbush, Harvard School of Public Health*

G.Gregory Raab, Raab & Associates, Inc.

Scott Ramsey, Fred Hutchinson Cancer Research Center†

David Ransohoff, University of North Carolina*†

Eddie Reed, Centers for Disease Control and Prevention

Laura Reid, Expression Analysis‡

Henry Rodriguez, National Cancer Institute

Jim Rollins, Centers for Medicare & Medicaid Services*

Charles L. Sawyers, University of California, Los Angeles*

Richard Schilsky, University of Chicago‡

Jeff Schomisch, Guide to Good Clinical Practice

Howard Schulman, PPD Biomarker Services*†

Katie Schutta, American Society for Clinical Oncology

Yvette Seger, The Center for Accelerating Medical Solutions

Richard M.Simon, National Cancer Institute*†

Dee Simons, Roche Diagnostics

Dominick Sinicropi, Genomic Health, Inc.

Margaret Spitz, MD Anderson Cancer Center‡

Juli Staiano, Foundation for the National Institutes of Health

Andrew Stevens, UK National Institute for Health and Clinical Excellence*

Zoltan Szallasi, Harvard Medical School‡

Brian Taylor, Expression Pathology, Inc.

Samantha Truex, Genzyme Corporation

Gayle Vaday, Congressionally Directed Medical Research Programs

John A. Wagner, Merck Research Laboratories*†

Judith Wagner, Institute of Medicine‡

Paul Waring, Genentech*

Barbara Weber, GlaxoSmithKline‡

Scott Weidman, National Research Council

Jean-Pierre Wery, Eli Lilly and Co.‡

Janet Woodcock, Food and Drug Administration*†

Timothy Yeatman, H. Lee Moffit Cancer Center & Research Institute

Brent Zanke, MD, Cancer Care Ontario†

Ann Zauber, Memorial Sloan-Kettering Cancer Center‡

Claire Zhu, National Cancer Institute

Piotr Zien, Advanced Medical Technology Association (AdvaMed)